a clinical study comparing the efficacy and safety of AUY922, aninvestigational compound, to standard treatments in patients withadvanced gastric cancer
- Conditions
- Patients with advanced gastric cancer who have progressed after one line of chemotherapyMedDRA version: 13.1Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 13.1Level: PTClassification code 10063916Term: Metastatic gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2009-015407-47-DE
- Lead Sponsor
- ovartis Pharma Services AG
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 120
- Radiologically confirmed advanced gastric cancer
- One previous line of chemotherapy
- Progressive disease
- One measurable lesion
- Blood tests within protocol ranges
XML File Identifier: 25j+VdeonRVbBJZ/1OraTJe1XyY=
Page 19/29
- (WHO) Performance Status = 1
- Able to sign informed consent
Other protocol-defined inclusion criteria may apply
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
- No symptomatic brain metastases
- No coumarin type anticoagulants
- No liver or kidney disease
- No impaired heart function
- No pregnant or lactating women
Other protocol-defined exclusion criteria may apply
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method